Breakthrough Cancer Drug Achieves Landmark FDA Approval
Credit: PixabayPromising cancer drug dostarlimab is advancing toward broader availability after receiving Breakthrough Therapy Designation from the FDA. This designation aims to expedite its development and market approval, potentially cutting years off its timeline if further testing is successful.Dostarlimab (Jemperli), a PD-1-blocking antibody, showed groundbreaking results in clinical trials, eliminating rectal cancer tumors without...